Corundum Systems Biology Inc. has invested in Freya Biosciences to advance women's reproductive health through innovative microbial immunotherapies.

Target Company Overview

Freya Biosciences is a clinical-stage biotech company based in Copenhagen, Denmark, and Boston, Massachusetts. The company is dedicated to advancing women's health, specifically through innovative approaches in reproductive immunotherapy. Its primary focus is on developing solutions to address infertility, particularly for women facing dysbiotic vaginal microbiota during assisted reproductive technology (ART) processes such as in vitro fertilization (IVF).

Freya utilizes vaginal microbial immunotherapeutics to create improved treatment options, aiming to address the critical gap in reproductive health therapies available for women. By harnessing the power of microbiome research, Freya Biosciences is poised to redefine fertility treatments and create enhanced pathways to optimal reproductive health for individuals seeking assistance.

Industry Overview in Japan and Korea

The reproductive health and biotechnology industry in Japan and Korea has shown significant growth, largely driven by increasing awareness and demand for assisted reproductive techniques, including IVF. Bo